Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low-intermediate and high risk patients

被引:14
作者
Valdagni, Riccardo [2 ]
Nahum, Alan E.
Magnani, Tiziana [2 ]
Italia, Corrado [3 ]
Lanceni, Angelo [4 ]
Montanaro, Paolo [5 ]
Rancati, Tiziana [2 ]
Avuzzi, Barbara [2 ]
Fiorino, Claudio [1 ]
机构
[1] Ist Sci San Raffaele, Dept Med Phys, I-20132 Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Prostate Program, Sci Directors Off, Milan, Italy
[3] Osped Riuniti Bergamo, Bergamo, Italy
[4] Azienda Osped Busto Arsizio, Arsizio, Italy
[5] Casa Cura Pio X, Med Oncol, Milan, Italy
关键词
Prostate cancer; Conformal radiotherapy; Hyperfractionation; alpha/beta; HYPOFRACTIONATED CONFORMAL RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; ALPHA/BETA RATIO; RADIATION-THERAPY; PHASE-II; HYPOXIA; FAILURE; CARCINOMA; PREDICTS; TRIALS;
D O I
10.1016/j.radonc.2011.07.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: To report the long-term biochemical control of a non-randomized trial comparing standard (STD) and hyper-fractionated (HFX) radiation schedules for prostate cancer treatment. Materials and methods: Between 1993 and 2003, 370 patients entered the study; 330/370 (STD: 179; HFX: 151) were evaluable for current analysis. Median doses were 79.2 Gy and 74 Gy for HFX (1.2 Gy/fr, two daily fractions) and STD (2 Gy/fr), respectively; median follow-up was 7.5 yr. The two regimens were compared in terms of biochemical relapse-free survival (according to ASTRO definition, bRFS) by univariate (log-rank test) and multivariate analyses (Cox regression hazard model). Based on published relationships between EQD2 and 5-yr biochemical control, alpha/beta values for each subgroup could be estimated. Results: 7.5 yr bRFS were 53.4% (+/- 4.4%, 95% CI) and 65.4% (+/- 4.0%) for HFX and STD, respectively (p = 0.13); HFX was associated with a poorer outcome in NCCN low + intermediate patients (7.5 yr bRFS: 56.6% vs 73.5%, p = 0.048) while no differences were seen for high-risk patients (7.5 yr bRFS: 44.1% vs 45.3%). Multivariate analysis revealed that NCCN risk grouping (high vs low + intermediate; OR: 0.59, p = 0.009) and age (< vs >= 70 yr; OR: 0.67, p = 0.03) were the main predictors of worse bRFS. In the subgroups of low + intermediate-risk patients <70 yr, the poorer outcome of HFX was more evident (7.5 yr bRFS: 47.1% vs 70.9%, p = 0.078) while no difference was seen for older patients (7.5 yr bRFS: 69.4% vs 72.0%, p = 0.76). Our alpha/beta estimates differ between low + intermediate-risk and high-risk patients. Conclusions: The bRFS long-term results of this non-randomized trial are consistent with different sensitivities to fractionation depending on NCCN risk grouping. The impact of age on the outcome of HFX for younger low + intermediate patients is consistent with an incomplete repair effect in older patients. (C) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 101 (2011) 454-459
引用
收藏
页码:454 / 459
页数:6
相关论文
共 47 条
[1]   The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer [J].
Abramowitz, Matthew C. ;
Li, Tiaynu ;
Buyyounouski, Mark K. ;
Ross, Eric ;
Uzzo, Robert G. ;
Pollack, Alan ;
Horwitz, Eric M. .
CANCER, 2008, 112 (01) :55-60
[2]  
[Anonymous], 2009, CLIN PRACT GUID ONC
[3]   A Phase III Randomized Study of High-dose Conventional vs. Hypofractionated Radiotherapy in Patients with High-risk Prostate Cancer [J].
Arcangeli, G. ;
Saracino, B. ;
Gomellini, S. ;
Petrongari, M. ;
Arcangeli, S. ;
Sentinelli, S. ;
Strigari, L. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03) :S79-S80
[4]  
Baumann M, 2010, RADIOTHER ONCOL, V96, P1, DOI 10.1016/j.radonc.2010.06.001
[5]   The α/β ratio for prostate cancer:: What is it, really? [J].
Bentzen, SM ;
Ritter, MA .
RADIOTHERAPY AND ONCOLOGY, 2005, 76 (01) :1-3
[6]  
Bentzen SM., 2009, Basic Clinical Radiobiology, V4th, P120
[7]   Toward optimal external-beam fractionation for prostate cancer [J].
Brenner, DJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :315-316
[8]  
Brenner DJ, 2002, INT J RADIAT ONCOL, V52, P6
[9]   Hypofractionation for prostate cancer radiotherapy - What are the issues? [J].
Brenner, DJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (04) :912-914
[10]   Fractionation and protraction for radiotherapy of prostate carcinoma [J].
Brenner, DJ ;
Hall, EJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (05) :1095-1101